Global /Australia /Healthcare /Biotechnology /RNV
chevron_leftBack
ReNerve Ltd. logo

ReNerve Ltd.

RNV
ASX: RNV Delayed
0.1100AUD 4.8%
0.0771 USD
As of 20 June 2026, ReNerve Ltd. has a market cap of $13.29M USD, ranking #39725 globally and #1228 in Australia. It ranks #3550 in the Healthcare sector, and #694 in the Biotechnology industry.
Global Rank
39725
Country Rank
1228
Sector Rank
3550
Industry Rank
694
Key Stats
Market Cap
$13.29MUSD
18.95M AUD
Enterprise Value
$10.47MUSD
14.93M AUD
Revenue (TTM)
$233.72KUSD
333.21K AUD
EBITDA (TTM)
-$3.63MUSD
-5.18M AUD
Net Income (TTM)
-$3.23MUSD
-4.61M AUD
PS Ratio
56.9
PB Ratio
3.6
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Julian Chick open_in_new
Founded
2016
Website
renerve.com.au open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
4.8% 5% 17% -15% -22% -22%

News

Loading...

Markets

Exchange Ticker Price
Australian Securities Exchange
MIC: XASX
PRIMARY
RNV
Renerve Ltd
ISIN: AU0000358616
TV:
SA:
YF:
GF:
BA:
RNV
MS:
0.1100 AUD
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About ReNerve Ltd.

ReNerve Limited, a medical device company, develops tissue-based products for peripheral nerve repair and replacement, and other related soft tissue surgical procedures. It develops NervAlign Nerve Cuff, a bioabsorbable protective wrap used to protect repaired nerves; and NervAlign bionic nerve and NervAlign Nerve Graft, an off-the-shelf, ready to use nerve structure for challenging nerve repairs. The company also offers deep dermal tissue product, a deep dermal product used in the repair of reconstructive and cosmetic surgical cases; amniotic tissue product ranges, used to aid the healing of wounds; NervAlign Nerve Conduit Range, a nerve conduit designed to facilitate nerve growth over short gaps between nerve ends; and NervAlign Nerve Guide Matrix for treating more severe nerve injuries, but eliminating the need for patients to undergo additional sural nerve harvesting. The company was incorporated in 2016 and is headquartered in Northcote, Australia.

Similar Companies

Industry: Biotechnology (Australia)
Name
Market Cap diff.
PE
CSL
$42.27B
60.27B AUD
318K%
29.3
$3.57B
5.09B AUD
27K%
-
MSB
$2.02B
2.88B AUD
15K%
-
PNV
$489.42M
697.75M AUD
4K%
71.8
$141.64M
965%
-
IMM
$65.12M
92.84M AUD
390%
-
Industry: Biotechnology (Global)
Name
Market Cap diff.
PE
AMGN
$182.42B
1M%
23.9
GILD
$159.92B
1M%
19.0
ARGX
$47.43B
41.39B EUR
357K%
39.9
$44.23B
68.19T KRW
333K%
35.5
LONN
$41.88B
33.71B CHF
315K%
37.2
068270
$27.74B
42.76T KRW
209K%
43.8
chevron_leftBack